Beta-blockers: research of the range, socio-economic availability and volume of consumption in ukraine
DOI:
https://doi.org/10.15587/2313-8416.2015.57212Keywords:
arterial hypertension, β-blockers, socio-economic availability, indicator of solvency adequacy, consumption, ATC/DDD methodologyAbstract
Beta-blockers (β-blockers) are widely used as a treatment of first choice for patients with arterial hypertension (HT). The numerous clinical studies data have shown that β-blockers hypotension effect is comparable with effects of the other first line antihypertensive remedies: calcium channel blockers, diuretics, ACE inhibitors, and angiotensin II receptor antagonists. According to the modern international recommendations for hypertension treatment, the use of selective β-blockers, as safer remedies comparing to the non-selective, is the most reasonable, but economic accessibility of remedies to the consumer is an important factor of influencing their consumption.
Aim. The analysis of the range, socio-economic availability and volume of consumption of beta-blockers in pharmaceutical market of Ukraine.
Methods. Statistical and marketing methods, WHO ATC/DDD methodology. Research objects – the data about the range, price, and the number of drug packages sold within a given year of information retrieval system “Morion”.
Results. At the beginning of 2014, in pharmaceutical market of Ukraine β-blockers were presented by 16 INN as 169 mainly foreign trade names. The group of selective β-blockers was the most widely presented – 76,6% from the general range. In 2013, the number of foreign drugs decreased by 16% compared to 2009. Propranolol, atenolol, and atenolol with chlorthalidone combination (Ca.s. = 0,21; 0,22; 0,37) were the most available; esmolol was the least available remedy. β-blockers volume of consumption has increased from 9,18 DIDs (2008) TO 13,48 DIDs (2013). The consumption of selective β-blockers was higher than both non-selective, and α- and β-blockers.
Conclusion. During 2009-2013 a decreasing of the total number of different groups of β-blockers was observed. The majority of β-blockers are high available for the average citizen of Ukraine, which allows the choice of drugs considering its efficacy, safety and cost. Esmolol drugs are the least available; propranolol and atenolol drugs are the most available. Over the period the consumption of selective β-blockers dominated, more effective and safe compared to non-selective. The displayed dynamics of consumption is a result of implementation of clinical protocols of medical care for hypertensive patients, formulary system, which promotes distribution of the evidence-based medicine principles in Ukrainian medical practice
References
Mancia, G., Fagard, R., Narkiewicz, K. et al. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 34 (28), 2159–2219. doi: 10.1093/eurheartj/eht151
Arterial hypertension. Updated and adapted clinical guidelines based on evidence (2012)., 129. Available at: http://www.dec.gov.ua/mtd/_ag.html
Kovalenko, V. M., Luta, M. I. (Eds.) (2011). Sercevo-sudynni zahvorjuvannja. Rekomendacii' z diagnostyky, profilaktyky ta likuvannja. Kyiv: MORION, 408.
Vasan, R. S., Larson, M. G., Leip, E. P., Kannel, W. B., Levy, D. (2001). Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. The Lancet, 358 (9294), 1682–1686. doi: 10.1016/s0140-6736(01)06710-1
Podzolkov, V. I., Tarzimanova, A. I. (2011). Mesto beta-adrenoblokatorov i diuretikov v lechenii arterial'noj gipertenzii. Lechebnoe delo, 1, 43–48.
Mishhenko, O. Ja., Adonkina, V. Ju., Chynush, I. V. (2012). Farmakoepidemiologichne doslidzhennja spozhyvannja beta-adrenoblokatoriv v Ukrai'ni. Zaporozhskyj medycynskyj zhurnal, 75 (6), 17–23.
Gromovyk, B. P., Gasjuk, G. D., Levyc'ka, O. R. (2004). Farmacevtychnyj marketyng: teoretychni ta prykladni zasady. Vinnycja: Nova Knyga, 464.
Jakovljeva, L. V., Mishhenko, O. Ja., Adonkina, V. Ju. (2015). Blokatory kal'cijevyh kanaliv: doslidzhennja asortymentu, social'no-ekonomichnoi' dostupnosti ta obsjagiv spozhyvannja v Ukrai'ni. Social'na farmacija v ohoroni zdorov’ja, 1 (1), 18–23.
Mnushko, Z. M., Timanjuk, I. V. (2007). Systema zabezpechennja dostupnosti likars'kyh zasobiv. Visnyk farmacii', 1 (49), 52–57.
Morozov, A. M., Jakovljeva, L. V., Stepanenko, A. V. et. al. (2013). Vyvchennja spozhyvannja likars'kyh zasobiv za anatomo-terapevtychno-himichnoju klasyfikacijeju ta vstanovlenymy dobovymy dozamy (ATS/DDD – metodologija). Kharkiv: Styl'-Yzdat, 34.
ATC/DDD Index 2016. Available at: http://www.whocc.no/atc_ddd_index/
Helfand, M., Peterson, K., Christensen, V. (2009). Drug Class Review: Beta Adrenergic Blockers. Drug Effectiveness Review Project, 616. Available at: http://www.ncbi.nlm.nih.gov/books/NBK47172/pdf/TOC.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Валентин Михайлович Толочко, Оксана Яківна Міщенко, Вікторія Юріївна Адонкіна
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
